Month: September 2026

VANCOUVER, BRITISH COLUMBIA, Sept. 16, 2026 (GLOBE NEWSWIRE) — HI-VIEW RESOURCES INC. (“Hi-View” or the “Company”) (CSE: GXLD; OTCQB: GXLDF; FSE: B630) announces that it has acquired the Jim Property in the Toodoggone Gold & Copper District of northern British Columbia. The Property is contiguous to Thesis Gold & Silver’s land package and lies near Evergold Corp.’s Golden Lion project.

R Nick Horsley, Chief Executive Officer of Hi-View, commented: “The Jim Property acquisition further adds to our existing land position in the Toodoggone district. The property is surrounded by Thesis Gold & Silver’s northern land package. With a gossanous zone visible at surface, we believe this could indicate hidden sulphide mineralization at depth, possibly associated with a copper porphyry system. We see this as a target worth following up on.”

Figure 1. Jim Property with gossanous zone highlighted.
Click here to view image

The Property hosts the historic ‘JM’ showing, first documented in 1988 and sits adjacent to Thesis Gold & Silver’s land package and near Evergold’s Golden Lion project.

Malachite staining with associated chalcopyrite, was noted throughout the area, lining fracture planes and associated with quartz and calcite stringers within narrow shears. The combination of copper sulphides and oxides with gold and silver values, localized in fractures, shears, and quartz-calcite veining, suggests an epithermal hydrothermal system with stronger mineralization potentially concealed beneath the gossanous zone. Historically, the area has only been prospected so further mapping and analyses are warranted to follow up on. We see this as an opportunity to advance an epithermal target in a district that already hosts the Kemess, Aurora, Lawyers, and Baker deposits.

Terms of the Agreement

The Company has acquired 100% interest in the Property from an arm’s length vendor by issuing 100,000 common shares of the Company, making a $5,000 cash payment, and granting the vendor a 2% net smelter returns royalty (NSR) on the Property, of which the Company has the right to buy back 1% for $1,000,000.

Qualified Person’s Statement

The technical content of this news release has been reviewed and approved by Nader Mostaghimi, P.Geo., The technical content of this news release has been reviewed and approved by Nader Mostaghimi, M.Sc., P.Geo. (EGBC #53441), Vice President of Exploration for the Company and a Qualified Person as defined by National Instrument 43-101.

About Hi-View Resources Inc.

Hi-View Resources Inc., a publicly listed mineral exploration company on the Canadian Securities Exchange, is advancing a portfolio of gold, silver, and copper assets in the Toodoggone region of northern British Columbia. The Company’s 100% owned and optioned projects cover more than 27,910 hectares and include the flagship Golden Stranger Project, the Lawyers claims, and the Borealis Project — all designated as high-priority targets. Additional properties under option include Saunders, Black Pearl, Oxide Summit, Nub, Ursus, Garnet, and Harmon Peak. The company also has an additional 1,300 hectares currently under mineral claim application. For more information, please visit Hi-View’s website or review the Company’s filings on SEDAR+ (www.sedarplus.ca).

On Behalf of the Board of Directors,
“R. Nick Horsley”
R. Nick Horsley, CEO

For further information, please contact:

Hi-View Resources Inc.
R. Nick Horsley – CEO
Email: info@hiviewresources.com
Telephone: (604) 343-4337
Website: www.hiviewgold.com

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.  Forward-looking statements in this news release includes statements related to the Incentive Program and the anticipated use of proceed therefrom. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release. 

WE SEEK SAFE HARBOUR

KKR joins Apollo as a minority participant

NEW YORK and LEVERKUSEN, Germany, Sept. 16, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Apollo-managed funds and affiliates (“Apollo”) have successfully closed a €3 billion capital solution for Bayer, previously announced on July 10. KKR has joined Apollo as a significant minority participant in the investment.

Under the transaction, Apollo, together with KKR, have invested equity capital into a newly established entity holding Bayer’s long-acting reversible contraceptives (LARC) business. Bayer retains a majority stake in the entity and continues to exercise full operational control over the business; there are no changes to the LARC strategy as a result of the investment.

Apollo Partner Jamshid Ehsani said, “We are proud to serve as a capital partner to Bayer, originating and leading a multi-billion-euro capital solution tailored to their needs. Bayer, a global life sciences leader and iconic German company, represents the types of large, blue-chip companies we serve through our High Grade Capital Solutions business.”

Ehsani added, “Apollo has committed to deploying more than $100 billion in Germany over the coming decade, and Bayer exemplifies the kind of strategic, long-term partnership we seek to build with the country’s most important companies.”

Centerview Partners served as financial advisor to the Apollo Funds. Latham & Watkins LLP, Paul, Weiss, Rifkind, Wharton & Garrison LLP, and NautaDutilh N.V. are legal counsel to the Apollo Funds.

About Apollo
Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees and the communities we impact, to expand opportunity and achieve positive outcomes. As of June 30, 2026, Apollo had approximately $1.05 trillion of assets under management. To learn more, please visit www.apollo.com.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Contacts:

Apollo

Noah Gunn
Global Head of Investor Relations
(212) 822-0540
IR@apollo.com

Joanna Rose
Global Head of Corporate Communications
(212) 822-0491
Communications@apollo.com / EuropeanMedia@apollo.com

KKR

Julia Leeger
+44 20 7839 9800
media@kkr.com

Bayer

Investor Relations: ir@bayer.com
Corporate Media Relations: christian.hartel@bayer.com

LONDON, Sept. 16, 2026 (GLOBE NEWSWIRE) — The Lake District has emerged as Britain’s capital of romantic stays, according to new data from leading travel search engine KAYAK.

KAYAK’s search data also points to growing interest for more indulgent escapes, with luxury and romantic stays seeing the biggest gains in accommodation searches, up 13% and 7% year-on-year respectively.

With new adaptations of Wuthering Heights, Sense and Sensibility and Pride and Prejudice putting literary romance in the spotlight in 2026, KAYAK analysed bookable UK accommodation to identify the destinations with the highest proportion of properties categorised as romantic.

Windermere topped the ranking, with more than one in three properties (36%) meeting the criteria. Keswick placed second at 35% and is also among the fastest-rising destinations in KAYAK searches. Harrogate ranked third, followed by Cheltenham and Penzance.

Britain’s most romantic getaway destinations

1. Windermere (36%)
2. Keswick (35%)
3. Harrogate (33%)
4. Cheltenham (32%)
5. Penzance (32%)
6. Stratford-upon-Avon (31%)
7. Sidmouth (30%)
8. Ambleside (29%)
9. Canterbury (29%)
10. Leeds (29%)

Rachel Mumford, KAYAK UK travel expert, said, “There’s something undeniably romantic in seeing a place that reminds you of a great British love story.

“And there seem to be a clear trend in staying somewhere that’s fuelled by nostalgia and a growing fascination with the ‘olden days’.

“From lakeside walks and historic towns to cosy hotels and dramatic coastlines, these destinations have many of the ingredients people associate with a classic. And with Autumn’s arrival – it’s the perfect time to swap the city break for something a little slower and more atmospheric.”

For an autumn escape, KAYAK recommends these top 5 stays in the top 5 most romantic towns:

• Windermere: Beech Hill Hotel & Spa for a classic lakeside stay.
• Keswick: Keswick Country House Hotel for a countryside escape.
• Harrogate: Crowne Plaza Harrogate for period-drama energy.
• Cheltenham: Hotel du Vin & Bistro Cheltenham for regency romance.
• Penzance: Hotel Penzance for a rugged coastal retreat.

About KAYAK  

KAYAK, part of Booking Holdings (NASDAQ: BKNG), is a leading travel search engine. With billions of queries across our platforms, we help people find their perfect flight, stay, rental car and vacation package. Trusted by millions of travellers, the KAYAK app makes travel planning seamless on iOS and Android, and we also support business travellers with our corporate travel solution.  

CONTACT: For more information and imagery, please contact kayak@ready10.media

Press Release
Nokia Defense and C3IA partner to accelerate digital transformation across UK defense operations

• Partnership combines Nokia Defense’s advanced connectivity with C3IA’s systems engineering, capability integration and security services expertise to support UK defense modernization.
• Focuses on delivering resilient multi-domain capabilities spanning tactical communications, C2, sensing, autonomous systems and edge computing.
• Builds on Nokia Defense and C3IA’s participation in the UK MOD TacSys framework to enhance tactical communications and interoperability.

16 September 2026
Espoo, Finland – At the 2026 DVD (Defence Vehicle Dynamics) event, Nokia Defense and C3IA, a UK specialist in systems engineering, capability integration and security services, announced the signing of a memorandum of understanding (MoU) to strengthen collaboration and support the digital transformation of UK Defense. The partnership combines Nokia’s expertise in advanced connectivity with C3IA’s engineering, capability integration, support and security services to help deliver next-generation defense capabilities for modern, multi-domain operations.

Together, the companies will deliver resilient communications, secure information sharing and network interoperability across land, air, maritime, cyber and space domains. The collaboration also builds on Nokia Defense and C3IA’s participation in the UK Ministry of Defence (MOD) Tactical Communication Systems (TacSys) framework, providing access to Nokia’s full connectivity portfolio from headquarters to the tactical edge.

Modern military operations increasingly depend on the ability to securely connect people, platforms, sensors and data across multiple domains. Under the agreement, Nokia Defense and C3IA will co-develop solutions across tactical and operational communications, private 4G and 5G, situational awareness, command and control (C2), sensing, autonomous systems and edge computing. The collaboration will focus on translating advanced communications technologies into practical, integrated capabilities that address real operational requirements for the defense sector.

“Through this collaboration with C3IA, we are combining resilient, mission-critical connectivity with expertise in defense systems engineering and support services to help turn technology into operational capability and advance tactical communications and interoperability across future UK defense programs,” said Mikko Viitaniemi, Vice President and Head of Nokia Defense.

“Delivering defense capability at pace requires more than technology alone. It requires the right combination of secure communications, sector expertise and systems integration. Our partnership with Nokia enables the rapid deployment of innovative capabilities that can deliver real operational value on the battlefield. Ultimately, our shared goal is to connect the battlespace, strengthen national security, and help equip the MOD for the future,” said Steve Brown, Managing Director, C3IA.

Nokia Defense and C3IA participate in the UK Government’s TacSys framework (RM6393) in Lot 1 (Services) and Lot 3 (Components), giving the UK MOD and other public sector organizations the ability to procure Nokia’s connectivity portfolio to support future tactical communications requirements.

Nokia Defense provides secure, intelligent connectivity for defense in the AI era. Built on Nokia’s global leadership across fixed, mobile, and transport networks, it delivers resilient, mission-ready communications solutions that strengthen national security and support critical operations worldwide.

Multimedia, technical information and related news
Web Page: www.nokia.com/defense-communications
Web Page: www.c3ia.co.uk

About Nokia
Nokia is the world’s leading provider of network technology and enables a new era of artificial intelligence. We are developing the networks of the future that connect people, devices and intelligence. Our network solutions span fixed and mobile networks, as well as IP, optical, core, and data center networks. Our secure, AI-native network infrastructure enables the application and utilization of AI on a global scale.

About C3IA
C3IA provides technical and security services across both public and private sectors. Specialising in systems engineering, ICT, information assurance, and NCSC-assured cyber services, C3IA plays a pivotal role in supporting the delivery of critical defence programmes. C3IA is dedicated to building long-lasting relationships with our clients, partners and community, delivering exceptional value through our commitment to quality and collaboration.

Media inquiries
Nokia Press Office
Email: Press.Services@nokia.com

Follow us on social media
LinkedIn X Instagram Facebook YouTube

• New data will highlight the breadth of semaglutide evidence across the cardiometabolic spectrum, including obesity, type 2 diabetes, cardiovascular, kidney and fatty liver disease, and new data on Wegovy® pill, Wegovy® 7.2 mg and Ozempic® 2.0 mg
• Real-world evidence from the OCTANE study will provide insights into Wegovy® pill use in adults with overweight or obesity, including weight outcomes, treatment switching and patient-reported outcomes
• CagriSema and amylin-based pipeline data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health (bone remodelling mechanisms). The data will advance our understanding of the underlying biology of obesity and type 2 diabetes and inform next-generation cardiometabolic innovation.

Bagsværd, Denmark, 16 September 2026 – Novo Nordisk today announced that new data from its cardiometabolic pipeline and portfolio will be presented at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, from 28 September to 2 October. The data to be presented at EASD will bring new scientific insights shared across obesity, type 2 diabetes, cardiovascular, kidney and liver-related outcomes. Together, the presentations reflect Novo’s continued focus on advancing understanding and treatment of interconnected cardiometabolic diseases to help many more patients.

A total of 44 abstracts will be presented, including data across semaglutide, CagriSema, and zenagamtide. Key presentations will include real-world evidence on Wegovy® pill and CagriSema data exploring appetite regulation, eating behaviour and brain responses to food cues using fMRI (functional Magnetic Resonance Imaging; a non-invasive brain scan that shows which areas of the brain are active during specific tasks or while at rest), and CagriSema data in type 2 diabetes looking at body composition, organ-level fat and bone remodelling mechanisms. Additional presentations include data on semaglutide addressing excess liver fat in people with obesity, and real-world evidence comparing major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg versus switching to tirzepatide.

“At EASD 2026 we are sharing the breadth and progression of our cardiometabolic portfolio and pipeline, including key insights that show how our science could make a difference in the everyday lives of people living with obesity, diabetes and related diseases,” said Martin Holst Lange, executive vice president of Research & Development and chief scientific officer at Novo. “We are presenting real-world data on Wegovy® pill, new insights into the broader benefits of semaglutide across Wegovy® and Ozempic®, and CagriSema research exploring food noise, brain responses and body composition. Together, these findings have the potential to shape the next generation of cardiometabolic care and reflect our ambition to develop treatments that can help us work towards more meaningful outcomes for patients.”

Media are invited to listen to an International Press Briefing on Wednesday, 30 September 2026, during EASD in Milan. The event will be accessible via a webcast on the Novo website, sign up via this link: Novo Nordisk: EASD International Press Briefing, 30 September 2026 (Virtual only)

Summary of presentations
Accepted data at the 62^nd Annual Meeting of the EASD include the following oral presentations and short oral discussions. Accepted abstracts include preliminary data that may be subject to change in the final published manuscripts. Dates and times of the presentations can be found on the EASD website.

Select Novo abstracts to be presented at EASD’s 2026 Scientific Sessions:

EASD Scientific symposium:

• REIMAGINE 1,2 and 3 Trial: Trial designs, key results and clinical perspectives: Scientific Session presentation (S21: Amylin in diabetes and obesity: What’s new?) – Wednesday 30 September; 16:30 – 17:30 CEST

Novo oral presentations and short oral discussions:

CagriSema (diabetes and obesity)

• Efficacy of CagriSema on body composition in participants with early type 2 diabetes: REIMAGINE 1. Oral presentation (LBA 11) – Tuesday 29 September; 14:45–16:15 CEST
• Effect of CagriSema on achievement of composite HbA_1c and weight reduction targets in participants with type 2 diabetes: REIMAGINE 1. Oral presentation (LBA 12) – Tuesday 29 September; 14:45–16:15 CEST
• fMRI – Effects of CagriSema on appetite, eating behaviour and food cue reactivity using functional MRI in adults with overweight or obesity. Oral presentation (122) – Wednesday 30 September; 14:30–16:00 CEST

Cagrilintide

• Impact of cagrilintide 2.4 mg on physical function: post-hoc patient-reported outcomes from REDEFINE 1. Short oral discussion (593) – Tuesday 29 September; 12:00–13:00 CEST

Zenagamtide (diabetes)

• Zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist: phase 2b results in type 2 diabetes. Oral presentation (13) – Wednesday 30 September; 9:45–11:15 CEST

Wegovy® (injection and tablets)

• OCTANE RWE US study: 3-month real-world weight outcomes among patients with overweight or obesity after switching from injectable semaglutide or tirzepatide to oral semaglutide for weight management. Short oral discussion (LBA 59) – Wednesday 30 September; 11:45–12:45 CEST
• Effect of semaglutide on liver measures and indices: pooled analysis from the STEP UP studies. Short oral discussion (529) – Thursday 1 October; 12:45–13:45 CEST

Ozempic®

• COMPETE SWITCH CV: Major adverse cardiovascular events in adults with type 2 diabetes escalating to semaglutide 2.0 mg vs switching to tirzepatide: Short oral discussion (LBA 44) – Tuesday 29 September; 12:00–13:00 CEST
• Sema 2.0-7.2 bridging: Pharmacometric modelling of escalating to subcutaneous semaglutide once-weekly 7.2 mg from 2.0 mg in a STEP UP T2D population: predicting weight reduction and gastrointestinal tolerability. Short oral discussion (824) – Tuesday 29 September; 13:15–14:15 CEST
• Post-hoc analysis from SUSTAIN FORTE: Achievement of HbA1c, body weight loss and hypoglycaemia composite endpoints with once-weekly semaglutide 2.0 mg versus 1.0 mg in T2D. Short oral discussion (828) – Tuesday 29 September; 13:15–14:15 CEST
• SUSTAIN OPTIMIZE CGM: Continuous glucose monitoring outcomes with once-weekly s.c. semaglutide 2.0 mg added to dose-reduced basal insulin vs dose-titrated basal insulin in adults with type 2 diabetes: Oral presentation (14) – Tuesday 29 September; 10:00–11:30 CEST
• FLOW mediation analysis: Evidence from mediation analysis of 72 pre-specified cardio-kidney-metabolic proteins: Oral presentation (LBA 30) – Thursday 1 October; 15:30–17:00 CEST
• FLOW trial plasma proteomics: identifies prognostic signatures and pharmacodynamic pathway modulation by semaglutide. Oral presentation (LBA 28) – Thursday 1 October; 15:30–17:00 CEST
• Semaglutide RWE in China T2D (SPOTLIGHT): Semaglutide reduces the risk of cardiovascular and renal events in Chinese type 2 diabetes patients – a real-world retrospective database study. Short oral discussion (Event A, 733) – Tuesday 29 September; 12:00-13:00
• SPOTLIGHT primary prevention: Semaglutide reduces cardiovascular event risk in the primary prevention setting among Chinese patients with type 2 diabetes: a real-world retrospective cohort study. Short oral discussion (Event A, LBA 40) – Tuesday 29 September; 12:00-13:00
• SPOTLIGHT combination therapy: Semaglutide in combination use with SGLT2i reduces cardiovascular events compared to SGLT2i alone use in Chinese patients with type 2 diabetes. Short oral discussion (Event A, LBA 42) – Tuesday 29 September; 12:00-13:00

UBT251 (diabetes and obesity):

• UBT251 (obesity), a triple hormone receptor agonist in adults with overweight or obesity: a multicenter, double-blind, placebo-controlled, randomized, phase 2 trial. Short oral discussion (Event D, 797) – Wednesday 30 September; 13:00–14:00 CEST
• UBT251 (diabetes), a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial. Oral presentation (124) – Wednesday 30 September; 14:30–16:00 CEST

Insulin Icodec

• ONWARDS 10 CGM-based metrics: Continuous glucose monitoring-based metrics in adults switching to once-weekly icodec without an initial one-time additional dose vs once-daily glargine U100. Post hoc analysis of ONWARDS 10. Short Oral discussion (Event F, 860) – Thursday 1 October; 14:00–15:00 CEST

IcoSema

• COMBINE 4 BL BMI: Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline BMI: COMBINE 4. Short oral discussion (854) – Thursday 1 October; 12:45–13:45 CEST
• COMBINE 4 BL HbA_1c: Efficacy and hypoglycaemia outcomes with once-weekly IcoSema vs glargine U100 in T2D by baseline HbA_1c: COMBINE 4. Short oral discussion (853) – Thursday 1 October; 12:45–13:45 CEST

About semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of the naturally occurring hormone GLP-1, which regulates blood sugar and body weight. Semaglutide has been tested in several robust clinical development programmes and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease and other related cardiometabolic diseases. Semaglutide is marketed under the brand names Wegovy® (injection or tablet), Ozempic® (injection or tablet) and Rybelsus® (tablet).

About CagriSema
CagriSema is being investigated by Novo as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.

About Fatty liver disease
Fatty liver disease – also known as MASH (metabolic dysfunction-associated steatohepatitis) – is a common condition in which excess fat builds up in the liver. Over time, this can cause inflammation and liver damage, especially in people with obesity, type 2 diabetes or other metabolic health conditions. The disease can range from mild fat buildup to more serious forms that may lead to scarring and reduced liver function.

About zenagamtide
Zenagamtide, formerly known as amycretin, is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo to provide a treatment for adults with overweight or obesity (AMAZE programme) and as a treatment for adults with type 2 diabetes (AMBITION programme). Zenagamtide is under investigation for oral and subcutaneous administration.

About type 2 diabetes
Type 2 diabetes is a chronic condition that affects how the body processes blood sugar (glucose) for energy. 589 million adults (20-79 years) are living with diabetes – 1 in 9. This number is predicted to rise to 853 million by 2050. Diabetes was responsible for 3.4 million deaths in 2024 – 1 every 9 seconds.

About obesity
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. Obesity is influenced by a variety of factors, including genetics, social determinants of health and the environment.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com	Alex Bruce (US) +1 640 230 0276 axeu@novonordisk.com

Attachment

• PR260916-EASD-curtain-raiser